Conclusion Concerns about Hims' GLP-1 strategy appear largely overblown The company is likely operating within legal boundaries and has a strong legal team Even if Novo sued for patent infringement, the most likely outcome would be a settlement with minimal negative impact In sum, it appears that concerns over the decision by Hims to continue to compound personalized versions of GLP-1 weight loss drugs past the enforcement deadlines set by the FDA are misplaced
Nuts and Seeds: Almonds, walnuts, and chia seeds provide essential fatty acids and can be satisfying snacks
Whether its managing side effects, adjusting dosages, or answering treatment-related questions, support is always available
In addition, HoltWinters forecast models were used to predict the number of PBS/RPBS semaglutide and dulaglutide prescriptions supplied each month between February and September 2022
Dose titration decisions are made by the Arora Health clinician based on your clinical response - not by Trimi's platform, and not by you
